Ipamorelin vs MK-677 (Ibutamoren): Which GH Secretagogue Is Right for You? (2026)

Ipamorelin vs MK-677: Which GH Secretagogue Fits Your Protocol?

Ipamorelin is a selective injectable peptide that pulses GH for 4 to 6 hours without raising cortisol or prolactin. MK-677 is an oral ghrelin mimetic that sustains GH and IGF-1 for 24 hours but raises fasting glucose, worsens insulin sensitivity, and stimulates appetite. Choose ipamorelin for metabolic neutrality; choose MK-677 for oral convenience if you can tolerate the glucose tradeoff.

How Each Compound Works

Ipamorelin: Selective Pulsatile Release

Ipamorelin (NNC 26-0161) is a synthetic pentapeptide and a potent agonist of the ghrelin receptor (GHS-R1a). Unlike its predecessors GHRP-6 and GHRP-2, it was engineered specifically for selectivity. Ipamorelin stimulates GH release without concomitant elevation of cortisol, ACTH, or prolactin, even at doses 300-fold above the threshold required for GH release. Ankersen 1998.

After subcutaneous injection, GH peaks at approximately 30 to 60 minutes and returns to baseline within 4 to 6 hours. Ishida & Saitoh 2020 describe this as closely mimicking the physiological ultradian GH rhythm. Pulsatile signalling maintains receptor sensitivity; continuous elevation tends to downregulate downstream responsiveness over time. Plasma half-life in animal pharmacokinetic studies runs approximately 2 hours, with roughly 20% intranasal bioavailability and primary urinary excretion. Johansen et al. 1998 showed ipamorelin has 5-fold lower plasma clearance than GHRP-6, partially explaining its more sustained post-injection GH pulse compared to older secretagogues. Independent selectivity data also confirms minimal cortisol, prolactin, or ACTH effect, one of the reasons practitioners describe ipamorelin as the cleanest GHRP studied to date.

MK-677 (Ibutamoren): Oral, Non-Peptide, Sustained

MK-677 is a non-peptide small molecule that activates the same GHS-R1a receptor via the orthosteric binding pocket shared by ghrelin and peptide secretagogues. Wang et al. 2021 used cryo-EM structures to map this binding pocket precisely. Its oral bioavailability is the primary commercial draw. At 25 mg daily, MK-677 produces a sustained 24-hour elevation of GH and IGF-1. The two-year randomised, placebo-controlled trial in 65 healthy older adults remains the largest human dataset: fat-free mass increased roughly 1.1 kg versus a 0.5 kg loss in placebo, GH and IGF-1 rose to young-adult levels, but fasting glucose increased and insulin sensitivity declined over the study period. Nass et al. 2008. Strength and functional outcomes did not improve despite the lean mass gain.

MK-677 does not simply increase GH. As a full ghrelin mimetic, it activates hypothalamic appetite circuits, glucose metabolism pathways, and fluid retention mechanisms simultaneously. This is not a side-effect profile vendors selling MK-677 tend to highlight.

The Selectivity Gap: Why It Matters

The single most important mechanistic difference is selectivity. Ipamorelin was engineered to separate GH release from the hormonal noise of older secretagogues; Ishida & Saitoh 2020 confirm it selectively increases plasma GH without changing prolactin or cortisol, even at pharmacologically extreme doses. MK-677 offers no equivalent selectivity. As a full ghrelin mimetic, it activates peripheral and central ghrelin receptor populations at once, producing appetite stimulation, elevated fasting glucose, and fluid accumulation in distal extremities as pharmacologically expected consequences rather than rare adverse effects. For men 35 and over tracking fasting glucose, HbA1c, or insulin sensitivity as part of a broader recovery and performance protocol, the metabolic signal from MK-677 deserves real weight before use.

Clinical Evidence Strength: What the Trials Actually Show

MK-677 Human Trials

Eight weeks of MK-677 at 25 mg daily in obese men increased bone resorption markers (CTX +26%, urinary hydroxyproline/creatinine ratio +23%) and elevated IGFBP-5 by 43 to 44%. Svensson et al. 1998. These reflect accelerated bone turnover, both resorption and formation activity. The Nass 2008 trial reported fasting glucose rising by roughly 0.3 mmol/L (about 5 mg/dL) on average with insulin sensitivity declining across the two-year period. Nass et al. 2008. Separately, a hip-fracture recovery trial in patients over 80 was terminated early after 6.5% of MK-677 recipients developed congestive heart failure versus 1.7% on placebo, alongside elevated blood pressure and glucose. That population was elderly and cardiovascularly vulnerable, but the signal is one any honest comparison has to flag rather than bury.

Ipamorelin Preclinical and Mechanism Data

Ipamorelin human RCT data is thinner than MK-677's. Most selectivity data comes from preclinical models and pharmacokinetic studies. Jiménez-Reina et al. 2002 found chronic ipamorelin treatment in rats increased somatotroph cell populations and GH granule density, suggesting trophic effects on pituitary GH-producing cells rather than simple receptor stimulation. For bone, Andersen et al. 2001 showed ipamorelin at 100 µg/kg three times daily subcutaneously for three months counteracted glucocorticoid-induced bone loss in rats, with periosteal bone formation rate increasing 4-fold versus glucocorticoid alone. For gastrointestinal function, Venkova et al. 2009 demonstrated ipamorelin significantly increased faecal output, food intake, and body weight gain in rodents with postoperative ileus, with dose-dependent GH release, a prokinetic profile distinct from MK-677 and one that reflects ipamorelin's broader downstream receptor distribution even while sparing cortisol and prolactin.

Dosing Protocols Compared

Anyone running either compound should track fasting glucose and blood pressure at baseline and at regular intervals. This is educational information about research use protocols, not a prescription; work with a qualified clinician if you have any metabolic risk factors before starting either compound.

Side Effects and Who Shouldn't Use Either

Ipamorelin's documented side effects in research settings are mild: transient injection-site redness, mild headache in a minority of users, and rare flushing. Its clean cortisol and prolactin profile is precisely why it's become the default ghrelin-pathway peptide in stacks. MK-677's side effect list is longer and more consequential: increased appetite (often significant), water retention in the hands and ankles, mild lethargy in the first weeks, transient muscle aches, and the glucose/insulin sensitivity effects documented above.

Skip MK-677 if you have any personal or family history of diabetes, prediabetes, or insulin resistance, since the diabetogenic signal is well-documented. Skip it also if you have any cardiac history, given the heart-failure signal in vulnerable populations. Skip ipamorelin if you're not prepared to handle subcutaneous injection technique and cold-chain storage, or if you're on any medication that interacts with growth hormone axis modulation. Neither compound should be used without physician oversight if you have active or historical cancer, since elevated IGF-1 carries theoretical concerns around tumor biology that remain unresolved in the literature.

Common Mistakes People Make Choosing Between Them

The most common mistake is picking MK-677 purely for convenience without accounting for the metabolic cost. If you're already managing borderline glucose numbers, the oral convenience is not worth the diabetogenic pressure. The second mistake is expecting ipamorelin injections to deliver MK-677-level 24-hour coverage; that's not how pulsatile GHRP pharmacology works, and stacking it with a GHRH analog like CJC-1295 addresses that gap rather than pushing ipamorelin dose higher. The third mistake is skipping baseline bloodwork. Fasting glucose, HbA1c, and lipid panels before and during either protocol are the only way to catch a metabolic shift early. The fourth mistake is sourcing either compound from unverified vendors; purity and dosing accuracy problems are common in this space, and checking how to read a peptide COA before you buy is a five-minute habit that prevents a wasted cycle.

Sourcing and Verification

Both compounds are widely sold as research chemicals, and quality control varies enormously between vendors. Before purchasing either, review how to know if peptides are real and cross-reference any batch against a certificate of analysis. We maintain our recommended sources for vendors that consistently provide third-party COAs; this is not a guarantee of outcome, but it materially reduces the odds of underdosed or contaminated product. If you're new to injectable peptides generally, how to inject peptides and how to reconstitute peptides cover the practical handling steps that matter more than most guides admit.

Related Stack Options

Ipamorelin is most commonly paired with a GHRH analog rather than run alone. The CJC-1295/ipamorelin stack protocol combines GHRH-pathway priming with ghrelin-pathway pulsing, and mechanistic synergy data in animal models shows GH secretion exceeding what either compound produces independently, though no direct human RCT of the combination itself has been published. If your goal is broader anti-aging and body composition support rather than pure GH secretagogue use, tesamorelin vs sermorelin and growth hormone secretagogues vs HGH lay out the broader landscape. For recovery-focused stacking outside the GH axis entirely, see peptide stacks that work.

This content is for educational purposes only. These compounds are intended for research use. Nothing here is medical advice; consult a qualified clinician before starting any GH secretagogue protocol, particularly if you have metabolic or cardiac risk factors.